The authors quantified serum lipoprotein (a) (Lp) (a) by enzymoimmunoanalysis in 86 outpatient men suffering peripheral vascular disease (PVD) and in 53 age-matched healthy men. They further measured serum cholesterol, serum triglycerides, low density lipoproteins-cholesterol, high density lipoproteins (HDL)-cholesterol and serum apolipoprotein B. Serum triglycerides were significantly increased in patients with PVD versus controls (148 ± 8 and 114 ± 7 mg/dL, mean ± SEM). HDL-cholesterol levels were significantly lower in patients versus controls (36 ± 1 and 43 ± 2 mg/dL, respectively). Serum Lp(a) levels in patients with PVD were 20 ± 2 mg/dL, whereas in controls they were 16 ± 3 (p: NS). Serum Lp(a) concentrations were identical in smoker and nonsmoker patients. There was no correlation between Lp(a) concentration and the other lipid parameters. Conversely, as occurs in coronary heart disease and in cerebrovascular disease, Lp(a) does not seem to be a marker for PVD, although a trend toward a higher mean levels was found.
Get full access to this article
View all access options for this article.
References
1.
Berg K.: A new serum type system in men: The Lp(a) system. Acta Pathol Microbiol Scand59:369-382, 1963.
2.
Armstrong VW , Walli AK, Seidel D.: Isolation, characterization, and uptake in human fibroblasts of and apo(a)-free lipoprotein obtained on reduction of lipoprotein (a). J Lipid Res26:1314-1323, 1985.
3.
Seman LJ, Breckenridge WC: Isolation and partial characterization of apolipoprotein (a) from human lipoprotein (a). Biochem Cell Biol64:999-1009, 1986.
4.
Fless GM,. Scanu AM: Lipoprotein (a): Biochemistry and biology. In: Biochemistry and Biology of Plasma Lipoproteins, ed. by Scanu AM, Spector AA.New York: Marcel Dekker, 1986, pp 73-83.
5.
Scanu AM: Lipoprotein (a). A potential bridge between the fields of atherosclerosis and thrombosis. Arch Pathol Lab Med112:1045-1047, 1988.
6.
Berg K., Dahlen G., Borresen A.: Lp(a) phenotypes, other lipoprotein parameters, and a family history of heart disease in middle-aged males. Clin Genet16:347-352, 1979.
7.
Kostner GM, Avogaro P., Cazzolato G., et al: Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis38:51-61, 1981.
8.
Durrington PN , Ishola M., Hunt L., et al: Apolipoproteins (a), AI, and B and parental history in men with early onset ischemic heart disease. Lancet1:1070-1073, 1988.
9.
Sandkamp M., Funke H., Schulte H., et al: Lipoprotein (a) is an independent risk factor for myocardial infarction at a young age. Clin Chem36:20-23, 1990.
10.
Kötringer P. , jürgens G.: A dominant role of lipoprotein (a) in the investigation and evaluation of parameters indicating the development of cervical atherosclerosis. Atherosclerosis58:187-198, 1985.
11.
Murai A., Miyhara T., Fujimoto N., et al: Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis59:199-204, 1986.
12.
Jürgens G., Költringer P.: Lipoprotein (a) in ischemic cerebrovascular disease: A new approach to the assessment of risk for stroke. Neurology37:513-515, 1987.
13.
Terpstra Ahm , Woodward Cjh, Sànchez-Muniz FJ: Improved techniques for the separation of serum lipoproteins by density gradient ultracentrifugation: Visualization by prestaining and rapid separation of serum lipoproteins for small volumes of serum. Ann Biochem111:149-157, 1981.
14.
Rosseneu M. , Vinaimont N., Vercaemst R., et al: Standardization of immunoassays for the quantitation of plasma apo B protein. Clin Chim Acta116:204-210, 1981.
15.
Labeur C., Michiels G., Bury J., et al: Lipoprotein Lp(a) quantified by enzyme-linked immunosorbent assay with monoclonal antibodies. Clin Chem35:1380-1384, 1989.
16.
Hughson WG, Mann JI, Garrod A.: Intermittent claudication: Prevalence and risk factors. Br Med Ji:1379-1381, 1978.
17.
Fowkes Fgr: Aetiology of peripheral atherosclerosis. Smoking seems especially important . Br Med J298:405-406, 1989.
18.
Schroll M., Munck O.: Estimation of peripheral arteriosclerotic disease by ankle blood pressure measurements in a population study of 60 year old men and women. J Chronic Dis34:261-269, 1981.
19.
Reunanen A. , Takkunen H., Aromaa A.: Prevalence of intermittent claudication and its effect on mortality. Acta Med Scand211:249-256, 1982.
20.
Lord JM: Cigarette smoking and peripheral atherosclerotic occlusive disease. JAMA191:249-251, 1965.
21.
Havel RJ: Familial dysbetalipoproteinemia. New aspects of pathogenesis and diagnosis . Med Clin North Am66:441-454, 1982.
22.
Pauciullo P., Carlson LA, Eklund B., et al: Concentration and chemical composition of plasma lipoprotein subfractions in patients with peripheral vascular disease. Evidence for normal apolipoprotein B but low cholesteryl ester content in small VLDL. Atherosclerosis58:123-137, 1985.
23.
Fowkes Fgr: Epidemiology of atherosclerosic arterial disease in the lower limbs. Eur J Vasc Surg2:283-291, 1988.
24.
Meerloo JM, Billimoria JD: High density lipoprotein cholesterol levels in peripheral vascular disease and in women on oral contraception. Atherosclerosis33:267-271, 1979.
25.
Schneider J. , Boldt J., Leyhe A., et al: HDL cholesterol, peripheral and coronary vascular disease in high age groups. Atherosclerosis35:487-489, 1980.
26.
Bihari-Vargi M., Szekely J., Gruber E.: Plasma high density lipoproteins in coronary, cerebral and peripheral vascular diseases. The influence of various risk factors . Atherosclerosis40:337-345, 1981.
27.
Masana L., Rubiés-Prat J., Nubiola AR, et al: Serum high-density lipoprotein cholesterol, heparin and peripheral vascular disease. Biomedicine35:42-43, 1981.
28.
Grundy SM: Hypertriglyceridemia: Mechanisms, clinical significance, and treatment. Med Clin North Am66:519-535, 1982.
29.
Eder HA, Gidez LI: The clinical significance of the plasma high density lipoproteins. Med Clin North Am66:431-440, 1982.
